MANP Platform
Unspecified R&D Program 1
Key Facts
About E-Star BioTech
E-Star BioTech is a private biotech company focused on advancing a platform of GC-A agonist peptides, with its lead asset MANP in Phase 2 development for resistant hypertension. The company has secured $36 million in grants and seed-stage private investment and holds an exclusive worldwide license from Mayo Clinic for MANP. With a strong scientific foundation and a seasoned leadership team, E-Star aims to bring a new class of therapeutics to the significant unmet need in hypertension and related cardiometabolic disorders.
View full company profileAbout E-Star BioTech
E-Star BioTech is a private biotech company focused on advancing a platform of GC-A agonist peptides, with its lead asset MANP in Phase 2 development for resistant hypertension. The company has secured $36 million in grants and seed-stage private investment and holds an exclusive worldwide license from Mayo Clinic for MANP. With a strong scientific foundation and a seasoned leadership team, E-Star aims to bring a new class of therapeutics to the significant unmet need in hypertension and related cardiometabolic disorders.
View full company profile